📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.

🧪

Mock / simulation document

This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.

📄

About this document — a plain-language guide

What it is. The Quality Target Product Profile (QTPP) and Critical Quality Attributes (CQAs).

Why it exists. Modern quality-by-design starts by defining what the product must achieve (QTPP) and which measurable attributes are critical to safety and efficacy (CQAs). Everything else in Module 3 flows from controlling these.

How it is produced here. No real manufacturing was done, so the chemistry, manufacturing, and controls detail is deep-knowledge mock — realistic, standard-conformant content standing in for real CMC data.

Format & governing standard. ICH Q8(R2) (QbD) · Q9(R1) (QRM) · Q11 · Q6B

Quality Target Product Profile (QTPP) & Critical Quality Attributes (CQA) — GLPI-103

Field	Value
Document ID	M3-QTPP
Version	2.0 (expanded)
Compound	GLPI-103 (GLP-1/APJ dual agonist peptide)
Standard	ICH Q8(R2) (QbD) · Q9(R1) (QRM) · Q11 · Q6B
Confidentiality	Confidential

[MOCK — deep-knowledge assumption] Quality-by-Design foundation linking the product profile to critical quality attributes, the risk assessment, and the control strategy (M3-CS).

Change History

Version	Date	Author	Summary
1.0	2026-06-29	CMC	Initial QTPP/CQA
2.0	2026-06-30	CMC	Expanded — full QTPP targets, CQA criticality ranking with clinical rationale, CMAs/CPPs, design space, control-strategy linkage

1. Quality Target Product Profile (QTPP)

🎯

Design quality backwards from the goal

Quality-by-design starts by writing down what the finished product must achieve (the QTPP) — things like dose, purity, and shelf life. Every later manufacturing and testing choice is justified by whether it protects one of these targets.

Element	Target
Indication / population	T2DM inadequately controlled on metformin (adults)
Dosage forms	(A) sterile IV solution 4 mg/mL, once weekly; (B) oral IR tablet 8 mg, once daily
Route / regimen	IV QW (pen, multidose); oral QD with titration (fasting administration)
Pharmacokinetics	Reproducible exposure supporting QW IV / QD oral; oral BA low but consistent
Efficacy-linked quality	Potency at GLP-1R and APJ within 80–125% of reference
Purity / safety	Related substances and aggregates within limits qualified for safety/immunogenicity
Sterility (IV)	Sterile, ≤ endotoxin limit, within sub-visible-particle limits
Container closure	Type I glass cartridge/pen (IV); HDPE + desiccant or Alu/Alu blister (oral)
Shelf life / storage	IV 24 mo at 2–8 °C; oral 24 mo at ≤30 °C desiccated (M3-STAB)

2. Critical Quality Attributes (CQAs) and Risk Ranking

🔬

Which properties are 'critical'

A Critical Quality Attribute is a measurable property that must stay in range to keep the product safe and effective (for a biologic, things like purity or aggregation). Identifying them tells everyone what absolutely must be controlled.

Criticality assessed (ICH Q9) from the severity of potential clinical impact (efficacy, safety, immunogenicity) and uncertainty:

2.1 Drug Substance

CQA	Clinical-impact rationale	Criticality	Control
Identity / primary sequence + lipidation site	Wrong sequence/conjugation → loss of efficacy or new immunogen	High	RP-HPLC + intact MS + peptide map
Assay / peptide content	Under/over-dosing	High	RP-HPLC + AAA
Sequence-variant & oxidation impurities	Reduced potency; potential immunogenicity	High	stability-indicating RP-HPLC
Aggregates / HMW species	Immunogenicity risk (parenteral)	High	SE-HPLC
des-lipid impurity	Altered PK (loss of half-life extension)	Medium	RP-HPLC
Endotoxin / bioburden	Parenteral safety	High	LAL / compendial
Potency (GLP-1R, APJ)	Efficacy (dual mechanism)	High	functional cell bioassays
Counter-ion / residual TFA / solvents	Safety	Medium	IC / GC (Q3C)

2.2 Drug Product

CQA	Clinical-impact rationale	Criticality	Control
Assay / content uniformity	Dose accuracy	High	RP-HPLC / USP <905>
Degradation products	Safety (Q3B)	High	RP-HPLC
Dissolution (oral, drug + SNAC)	Bioavailability (enhancer-dependent)	High	USP <711>
Sterility / endotoxin (IV)	Parenteral safety	High	USP <71> / LAL
Sub-visible particles / aggregates (IV)	Immunogenicity/safety	High	USP <788> / SE-HPLC
pH (IV)	Stability/tolerability	Medium	potentiometry
Water content (oral)	Enhancer/peptide stability	Medium	KF

3. Critical Material Attributes (CMAs) & Critical Process Parameters (CPPs)

From the QRM (FMEA), the attributes/parameters with the greatest effect on CQAs are:

CMAs: drug-substance purity & aggregate level; SNAC quality (oral absorption); polysorbate-80 quality (IV aggregation).
CPPs — drug substance: coupling completion (deletion sequences), preparative-HPLC pooling criteria (purity/des-lipid), lyophilisation moisture.
CPPs — IV: bulk pH, pre-filtration bioburden, aseptic fill integrity.
CPPs — oral: blend uniformity, compression force (hardness/disintegration), enhancer:drug ratio (dissolution/BA).

4. Design Space & Control Strategy Linkage

A multivariate design space (e.g., the oral enhancer:drug ratio × disintegration time, established by DoE) defines proven acceptable ranges within which CQAs are met without further regulatory post-approval change. Each CQA is assured by a combination of input-material controls, CPP/IPC controls, and release + stability specifications, with continued-process-verification monitoring — detailed in M3-CS (Control Strategy).